Stage-Specific Effect of N-(4-Hydroxyphenyl)Retinamide on Cell Growth in Squamous Cell Carcinogenesis

Molecular Carcinogenesis

Volumn 40, Issue 1, 2004, Pages 12-23

  Kabbout, Mohamed ^a   Hatoum, Asma ^a   Abou Lteif, Ghada ^a   Chakroun, Imane ^a   Homaidan, Fadia R ^a   Darwiche, Nadine ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Apoptosis; Cell cycle arrest; Neoplastic keratinocytes; Retinoid receptors

Indexed keywords

FENRETINIDE; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR GAMMA; RETINOID;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; CELL CYCLE; CELL CYCLE G1 PHASE; CELL GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG RECEPTOR BINDING; KERATINOCYTE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN CANCER; SPINDLE CELL; SQUAMOUS CELL CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZIMIDAZOLES; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; FENRETINIDE; G1 PHASE; KERATINOCYTES; MICE; MICE, INBRED BALB C; NEOPLASM STAGING; NEVUS, SPINDLE CELL; PAPILLOMA; PROPIDIUM; RECEPTORS, RETINOIC ACID; RIBONUCLEASES; TRETINOIN;

MURINAE;

EID: 2342613547     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.20016     Document Type: Article

References (55)

1. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990;323:795-801.
2. Moon TE, Levine N, Cartmel B, et al. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: A randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev 1997;6:949-956.
3. Darwiche N, Celli G, Tennenbaum T, Glick AB, Yuspa SH, De Luca LM. Mouse skin tumor progression results in differential expression of retinoic acid and retinoid X receptors. Cancer Res 1995;55:2774-2782.
4. Xu XC, Wong WY, Goldberg L, et al. Progressive decreases in nuclear retinoid receptors during skin squamous carcinogenesis. Cancer Res 2001;61:4306-4310.
5. Lotan R. Retinoids and apoptosis: Implications for cancer chemoprevention and therapy. J Natl Cancer Inst 1995;87:1655-1657.
6. Levine N. Role of retinoids in skin cancer treatment and prevention. J Am Acad Dermatol 1998;39:62-66.
7. Griffiths CM, Voorhees JJ. Human in vivo pharmacology of topical retinoids. Arch Dermatol Res 1994;287:53-60.
8. Zusi FC, Lorenzi MV, Vivat-Hannah V. Selective retinoids and rexinoids in cancer therapy and chemoprevention. Drug Discov Today 2002;7:1165-1174.
9. Gander RJ, Gurney JA. All-trans retinoic acid esters and amides. Chem Abstr 1978;88:89892.
10. Formelli F. Bioactivities of N-(4-hydroxyphenyl) retinamide. In: Livrea MA, editor. Vitamin A and retioids: An update of biological aspects and clinical applications. Basel, Boston, Berlin: Birkhäser Verlag; 2000. pp 241-250.
11. Wu JM, DiPietrantonio AM, Hsieh TC. Mechanism of fenretinide (4-HPR)-induced cell death. Apoptosis 2001;6:377-388.
12. Ulukaya E, Wood EJ. Fenretinide and its relation to cancer. Cancer Treat Rev 1999;25:229-235.
13. Costa A, Formelli F, Chiesa F, Decensi A, De Palo G, Veronesi U. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res 1994;54:2032-2037.
14. Veronesi U, De Palo G, Marubini E, et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 1999;91:1847-1856.
15. Follen M, Atkinson EN, Schottenfeld D, et al. A randomized clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix. Clin Cancer Res 2001;11:3356-3365.
16. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996;10:940-954.
17. Fanjul AN, Delias D, Pierotti MA, Rideout D, Qiu J, Pfahl M. N-(4-hydroxyphenyl) retinamide is a highly selective activator of retinoid receptors. J Biol Chem 1996;271:22441-22446.
18. Sun SY, Yue P, Lotan R. Induction of apoptosis by N-(4-hydroxyphenyl)retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis related genes in human prostate carcinoma cells. Mol Pharmacol 1999;55:403-410.
19. Goyette P, Chen CF, Wang W, Seguin F, Lohnes D. Characterization of retinoic acid receptor-deficient keratinocytes. J Biol Chem 2000; 275:16497-16505.
20. Vollberg TM, Sr., Nervi C, George MD, Fujimoto W, Krust A, Jetten AM. Retinoic acid receptors as regulators of human epidermal keratinocyte differentiation. Mol Endocrinol 1992;6:667-676.
21. Fisher GJ, Talwar HS, Xiao JH, et al. Immunological identification and functional quantitation of retinoic and retinoid X receptor proteins in human skin. J Biol Chem 1994;269:20629-20635.
22. de Thé H. Altered retinoic acid receptor. FASEB J 1996;10:955-960.
23. Hatoum A, El-Sabban ME, Khoury J, Yuspa SH, Darwiche N. Overexpression of retinoic acid receptors alpha and gamma into neoplastic epidermal cells causes retinoic acid-induced growth arrest and apoptosis. Carcinogenesis 2001;22:1955-1963.
24. Hennings H, Michael D, Cheng C, Steinert P, Holbrook K, Yuspa SH. Calcium regulation of growth and differentiation of mouse epidermal cells in culture. Cell 1980;19:245-254.
25. Yuspa SH, Morgan DL. Mouse skin cells resistant to terminal differentiation associated with initiation of carcinogenesis. Nature 1981;293:72-74.
26. Ha oncogene and form papillomas on skin grafts on athymic nude mouse hosts. Cancer Res 1988;48:165-169.
27. Greenhalgh DA, Welty DJ, Player A, Yuspa SH. Two oncogenes, v-fos and v-ras, cooperate to convert normal keratinocytes to squamous cell carcinomas. Proc Natl Acad Sci USA 1990;87:643-647.
28. Yuspa SH, Kilkenny AE, Steinert PM, Roop DR. Expression of murine epidermal differentiation markers is tightly regulated by restricted extracellular calcium concentrations in vitro. J Cell Biol 1989;109:1207-1217.
29. Formelli F, Clerici M, Campa T, et al. Five-year administration of fenretinide: Pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 1993;11:2036-2042.
30. Denning MF, Wang Y, Nickoloff BJ, Wrone-Smith T. Protein kinase C delta is activated by caspase-dependent proteolysis during ultraviolet radiation-induced apoptosis of human keratinocytes. J Biol Chem 1998;273:29995-30002.
31. Boise LH, Gonzalez-Garcia M, Postema CE, et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993;74:597-608.
32. Fisher GJ, Datta SC, Talwar HS, et al. Molecular basis of sun-induced premature skin ageing and retinoid antagonism. Nature 1996;379:335-339.
33. Formelli F, Barua AB, Olson JA. Bioactivities of N-(4-hydroxyphenyl) retinamide and retinoylβ-glucuronide. FASEB J 1996;10:1014-1024.
34. Bruno S, Tenca C, Saverino D, Ciccone E, Grossi CE. Apoptosis of squamous cells at different stages of carcinogenesis following 4-HPR treatment. Carcinogenesis 2002;23:447-456.
35. Zou CP, Kurie JM, Lotan D, Zou CC, Hong WK, Lotan R. Higher potency of N-(4-hydroxyphenyl)retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res 1998;4:1345-1355.
36. Oridate N, Suzuki S, Higuchi M, Mitchell MF, Hong WK, Lotan R. Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. J Natl Cancer Inst 1997;89:1191-1198.
37. D'Ambrosio SM, Gibson-D'Ambrosio R, Milo GE, et al. Differential response of normal, premalignant and malignant human oral epithelial cells to growth inhibition by chemopreventive agents. Anticancer Res 2000;20:2273-2280.
38. O'Donnell PH, Guo WX, Reynolds CP, Maurer BJ. N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes. Leukemia 2002;5:902-910.
39. Asumendi A, Morales MC, Alvarez A, Arechaga J, Perez-Yarza G. Implication of mitochondria-derived ROS and cardiolipin peroxidation in N-(4-hydroxyphenyl) retinamide-induced apoptosis. Br J Cancer 2002;12:1951-1956.
40. Chan LN, Zhang S, Shao J, Waikel R, Thompson EA, Chan TS. N-(4-hydroxyphenyl) retinamide induces apoptosis in T lymphoma and T lymphoblastoid leukemia cells. Leuk Lymphoma 1997;25:271-280.
41. Pergolizzi R, Appierto V, Crosti M, et al. Role of retinoic acid receptor overexpression in sensitivity to fenretinide and tumorigenicity of human ovarian carcinoma cells. Int J Cancer 1999;81:829-834.
42. Sani BP, Shealy YF, Hill DL. N-(4-hydroxyphenyl)retinamide: Interactions with retinoid-binding proteins/receptors. Carcinogenesis 1995;16:2531-2534.
43. Delia D, Aiello A, Lombardi L, et al. N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 1993;53:6036-6041.
44. Clifford JL, Menter DG, Wang M, Lotan R, Lippman SM. Retinoid receptor-dependent and -independent effects of N-(4-Hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. Cancer Res 1999;59:14-18.
45. Ponzoni M, Bocca P, Chiesa V, et al. Differential effects of N-(4-hydroxyphenyl) retinamide and retinoic acid on neuroblastoma cells: Apoptosis versus differentiation. Cancer Res 1995;55:853-861.
46. Weinberg WC, Azzoli CG, Chapman K, Levine AJ, Yuspa SH. p53-mediated transcriptional activity increases in differentiating epidermal keratinocytes in association with decreased p53 protein. Oncogene 1995;12:2271-2279.
47. Di Cunto F, Topley G, Calautti E, et al. Inhibitory function of p21Cip1/WAF1 in differentiation of primary mouse keratinocytes independent of cell cycle control. Science 1998;280:1069-1072.
48. Langenfeld J, Kiyokawa H, Sekula D, Boyle J, Dmitrovsky E. Posttranslational regulation of cyclin D1 by retinoic acid: A chemoprevention mechanism. Proc Natl Acad Sci USA 1997;94:12070-12074.
49. Spinella MJ, Freemantle SJ, Sekula D, Chang JH, Christie AJ, Dimitrovsky E. Retinoic acid promotes ubiquitination and proteolysis of cyclin D1 during induced tumor cell proliferation. J Biol Chem 1999;274:22013-22018.
50. Sun SY, Yue P, Lotan R. Induction of apoptosis by N-(4-hydroxyphenyl)retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis related genes in human prostate carcinoma cells. Mol Pharmacol 1999;55:403-410.
51. Faderl S, Lotan R, Kantarjian HM, Harris D, Van Q, Esrov Z. N-(4-hydroxylphenyl) retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL). Leuk Res 2003;27:259-266.
52. Maurer B, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP. Increase in ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl) retinamide in neuroblastoma cell lines. J Natl Cancer Inst 1999;91:1138-1146.
53. 1/S checkpoint regulators (cyclin D1, cdk4, pRB) and transient modulation of poly(ADP-ribose) polymerase and ceramide level changes by fenretinide N-(4-hydroxyphenyl) retinamide, 4-HPR) in human promyelocytic HL-60 leukemic cells. Int J Cancer 1998;78:53-61.
54. DiPietrantonio AM, Hsieh TC, Juan G, Tranganos F, Darzynkiewicz Z, Wu JM. Fenretinide-induced caspase 3 activity involves increased protein stability in a mechanism distinct from reactive oxygen species elevation. Cancer Res 2000;60:4331-4335.
55. Sun SY, Yue P, Hong WK, Lotan R. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through upregulation of TRAIL receptors in human lung cancer cells. Cancer Res 2000;60:7149-7155.